Advances in Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma

Louise J Murray; Laura A Dawson

doi:10.1016/j.semradonc.2017.02.002

Advances in Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma

Semin Radiat Oncol. 2017 Jul;27(3):247-255. doi: 10.1016/j.semradonc.2017.02.002. Epub 2017 Feb 20.

Authors

Louise J Murray¹, Laura A Dawson²

Affiliations

¹ Department of Radiation Oncology, University of Toronto, Toronto, ON, Canada; Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
² Department of Radiation Oncology, University of Toronto, Toronto, ON, Canada; Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada. Electronic address: laura.dawson@rmp.uhn.on.ca.

PMID: 28577832
DOI: 10.1016/j.semradonc.2017.02.002

Abstract

Stereotactic Body Radiation Therapy (SBRT) is an emerging effective treatment for hepatocellular carcinoma (HCC) associated with acceptable rates of toxicity in appropriately selected patients. Despite often being reserved for patients unsuitable for other local treatments, prospective and retrospective studies have demonstrated excellent long-term control. SBRT may be used as a stand-alone treatment, or as an adjunct to other HCC therapies. Based on available data, SBRT appears to complement existing local liver therapies. Randomized and nonrandomized comparative studies are required to better determine the optimal role of SBRT in HCC treatment.

Publication types

Review

MeSH terms

Carcinoma, Hepatocellular / radiotherapy*
Humans
Liver Neoplasms / radiotherapy*
Prospective Studies
Radiosurgery / methods*
Retrospective Studies